AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00181-07v1
51/11/4202    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huitric, E.
Right arrow Articles by Hoffner, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huitric, E.
Right arrow Articles by Hoffner, S. E.
Antimicrobial Agents and Chemotherapy, November 2007, p. 4202-4204, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00181-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor{triangledown}

Emma Huitric,1,2* Peter Verhasselt,3 Koen Andries,4 and Sven E. Hoffner1,2

Swedish Institute for Infectious Disease Control, Solna, Sweden,1 Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden,2 Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium,3 Tibotec N.V., Beerse, Belgium4

Received 7 February 2007/ Returned for modification 11 June 2007/ Accepted 13 August 2007

The diarylquinoline R207910 is in clinical development for tuberculosis treatment. The MIC50 for 41 drug-susceptible and 44 multidrug-resistant Mycobacterium tuberculosis clinical isolates was 0.032 µg/ml. Out of 20 additional mycobacterial species, three were found to be naturally resistant to R207910 and were shown to exhibit a polymorphism in their atpE genes.

* Corresponding author. Mailing address: Swedish Institute for Infectious Disease Control, Department of Bacteriology, S-171 82 Solna, Sweden. Phone: 46 8 4572473. Fax: 46 8 301797. E-mail: emma.huitric{at}smi.ki.se

{triangledown} Published ahead of print on 20 August 2007.

Antimicrobial Agents and Chemotherapy, November 2007, p. 4202-4204, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00181-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.